Focused On-demand Library for Centrosome and spindle pole-associated protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q1MSJ5

UPID:

CSPP1_HUMAN

Alternative names:

Alternative UPACC:

Q1MSJ5; A6ND63; Q70F00; Q8TBC1

Background:

Centrosome and spindle pole-associated protein 1, encoded by the gene with accession number Q1MSJ5, is implicated in cell-cycle-dependent microtubule organization. This protein plays a pivotal role in ensuring proper cell division and is integral to maintaining cellular integrity and function.

Therapeutic significance:

Joubert syndrome 21, a complex disorder characterized by cerebellar ataxia, oculomotor apraxia, and a range of other symptoms, is linked to mutations affecting this protein. Understanding the role of Centrosome and spindle pole-associated protein 1 could lead to novel therapeutic strategies for this syndrome, highlighting its potential as a target for drug discovery.